|
1
|
Bade BC and Dela Cruz CS: Lung Cancer
2020: Epidemiology, Etiology, and Prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang D, Liu Y, Bai C, Wang X and Powell
CA: Epidemiology of lung cancer and lung cancer screening programs
in China and the United States. Cancer Lett. 468:82–87. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug
resistance to targeted therapeutic strategies in non-small cell
lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan X, Jiao SC, Zhang GQ, Guan Y and Wang
JL: Tumor-associated immune factors are associated with recurrence
and metastasis in non-small cell lung cancer. Cancer Gene Ther.
24:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang
BS and Wu YC: Predictors of death, local recurrence, and distant
metastasis in completely resected pathological stage-I
non-small-cell lung cancer. J Thorac Oncol. 7:1115–1123. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Williams SJ, Wreschner DH, Tran M, Eyre
HJ, Sutherland GR and McGuckin MA: Muc13, a novel human cell
surface mucin expressed by epithelial and hemopoietic cells. J Biol
Chem. 276:18327–18336. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sheng YH, Lourie R, Lindén SK, Jeffery PL,
Roche D, Tran TV, Png CW, Waterhouse N, Sutton P, Florin TH, et al:
The MUC13 cell-surface mucin protects against intestinal
inflammation by inhibiting epithelial cell apoptosis. Gut.
60:1661–1670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimamura T, Ito H, Shibahara J, Watanabe
A, Hippo Y, Taniguchi H, Chen Y, Kashima T, Ohtomo T, Tanioka F, et
al: Overexpression of MUC13 is associated with intestinal-type
gastric cancer. Cancer Sci. 96:265–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chauhan SC, Vannatta K, Ebeling MC,
Vinayek N, Watanabe A, Pandey KK, Bell MC, Koch MD, Aburatani H,
Lio Y, et al: Expression and functions of transmembrane mucin MUC13
in ovarian cancer. Cancer Res. 69:765–774. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chauhan SC, Ebeling MC, Maher DM, Koch MD,
Watanabe A, Aburatani H, Lio Y and Jaggi M: MUC13 mucin augments
pancreatic tumorigenesis. Mol Cancer Ther. 11:24–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta BK, Maher DM, Ebeling MC, Stephenson
PD, Puumala SE, Koch MR, Aburatani H, Jaggi M and Chauhan SC:
Functions and regulation of MUC13 mucin in colon cancer cells. J
Gastroenterol. 49:1378–1391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng YH, He Y, Hasnain SZ, Wang R, Tong
H, Clarke DT, Lourie R, Oancea I, Wong KY, Lumley JW, et al: MUC13
protects colorectal cancer cells from death by activating the NF-κB
pathway and is a potential therapeutic target. Oncogene.
36:700–713. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tiemin P, Fanzheng M, Peng X, Jihua H,
Ruipeng S, Yaliang L, Yan W, Junlin X, Qingfu L, Zhefeng H, et al:
MUC13 promotes intrahepatic cholangiocarcinoma progression via
EGFR/PI3K/AKT pathways. J Hepatol. 72:761–773. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan S, Ebeling MC, Zaman MS, Sikander M,
Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D,
et al: MicroRNA-145 targets MUC13 and suppresses growth and
invasion of pancreatic cancer. Oncotarget. 5:7599–7609. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He L, Qu L, Wei L, Chen Y and Suo J:
Reduction of miR 132 3p contributes to gastric cancer proliferation
by targeting MUC13. Mol Med Rep. 15:3055–3061. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moniaux N, Escande F, Porchet N, Aubert JP
and Batra SK: Structural organization and classification of the
human mucin genes. Front Biosci. 6:D1192–D1206. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Filippou PS, Ren AH, Korbakis D,
Dimitrakopoulos L, Soosaipillai A, Barak V, Frenkel S, Pe'er J,
Lotem M, Merims S, et al: Exploring the potential of mucin 13
(MUC13) as a biomarker for carcinomas and other diseases. Clin Chem
Lab Med. 56:1945–1953. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim W, Ridge CA, Nicholson AG and
Mirsadraee S: The 8th lung cancer TNM classification and clinical
stageing system: Review of the changes and clinical implications.
Quant Imaging Med Surg. 8:709–718. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumari S, Khan S, Gupta SC, Kashyap VK,
Yallapu MM, Chauhan SC and Jaggi M: MUC13 contributes to rewiring
of glucose metabolism in pancreatic cancer. Oncogenesis. 7:192018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stiles ZE, Khan S, Patton KT, Jaggi M,
Behrman SW and Chauhan SC: Transmembrane mucin MUC13 distinguishes
intraductal papillary mucinous neoplasms from non-mucinous cysts
and is associated with high-risk lesions. HPB (Oxford). 21:87–95.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sheng Y, Ng CP, Lourie R, Shah ET, He Y,
Wong KY, Seim I, Oancea I, Morais C, Jeffery PL, et al: MUC13
overexpression in renal cell carcinoma plays a central role in
tumor progression and drug resistance. Int J Cancer. 140:2351–2363.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai Y, Liu L, Zeng T, Liang JZ, Song Y,
Chen K, Li Y, Chen L, Zhu YH, Li J, et al: Overexpression of MUC13,
a poor prognostic predictor, promotes cell growth by activating Wnt
signaling in hepatocellular carcinoma. Am J Pathol. 188:378–391.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Doxtater K, Sekhri R, Mishra U, Jaggi M,
Tripathi M and Chauhan S: MUC13 enhances anchorage independent
survival and cooperates with YAP1 and β-catenin towards colorectal
cancer metastasis. Cancer Res. 80 (Suppl):49162020.
|
|
26
|
Wang H, Shen L, Lin Y, Shi Q, Yang Y and
Chen K: The expression and prognostic significance of Mucin 13 and
Mucin 20 in esophageal squamous cell carcinoma. J Cancer Res Ther.
11 (Suppl 1):C74–C79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li P, Wang H, Hou M, Li D and Bai H:
Upstream stimulating factor1 (USF1) enhances the proliferation of
glioblastoma stem cells mainly by activating the transcription of
mucin13 (MUC13). Pharmazie. 72:98–102. 2017.PubMed/NCBI
|
|
28
|
Gupta BK, Maher DM, Ebeling MC, Sundram V,
Koch MD, Lynch DW, Bohlmeyer T, Watanabe A, Aburatani H, Puumala
SE, et al: Increased expression and aberrant localization of mucin
13 in metastatic colon cancer. J Histochem Cytochem. 60:822–831.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
LaMonte GM, Orjuela-Sanchez P, Calla J,
Wang LT, Li S, Swann J, Cowell AN, Zou BY, Abdel-Haleem Mohamed AM,
Villa Galarce ZH, et al: Dual RNA-seq identifies human mucosal
immunity protein Mucin-13 as a hallmark of Plasmodium
exoerythrocytic infection. Nat Commun. 10:4882019. View Article : Google Scholar : PubMed/NCBI
|
